Certara (NASDAQ:CERT) Stock Price Up 10.5% – Still a Buy?

Posted by Francis Steltz on Jun 16th, 2026

Certara, Inc. (NASDAQ:CERT – Get Free Report)’s share price rose 10.5% on Tuesday . The stock traded as high as $5.61 and last traded at $5.7550. Approximately 396,739 shares changed hands during mid-day trading, a decline of 89% from the average daily volume of 3,459,407 shares. The stock had previously closed at $5.21.

Wall Street Analysts Forecast Growth

CERT has been the subject of several research reports. Robert W. Baird dropped their target price on shares of Certara from $7.00 to $6.00 and set a “neutral” rating for the company in a report on Tuesday, May 12th. Morgan Stanley dropped their target price on shares of Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Barclays dropped their target price on shares of Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Certara in a research note on Friday, May 29th. Finally, TD Cowen restated a “buy” rating on shares of Certara in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $8.85.

Check Out Our Latest Stock Report on CERT

Certara Trading Up 15.5%

The company’s 50 day simple moving average is $5.58 and its 200 day simple moving average is $7.15. The firm has a market cap of $935.75 million, a price-to-earnings ratio of -59.93 and a beta of 1.49. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88.

Certara (NASDAQ:CERT – Get Free Report) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). The business had revenue of $106.92 million during the quarter, compared to analyst estimates of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business’s revenue was up .8% on a year-over-year basis. During the same quarter last year, the firm earned $0.14 EPS. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, research analysts expect that Certara, Inc. will post 0.24 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Certara

A number of institutional investors and hedge funds have recently modified their holdings of CERT. Dixon Mitchell Investment Counsel Inc. purchased a new stake in Certara in the third quarter valued at $10,587,000. Fort Washington Investment Advisors Inc. OH lifted its position in Certara by 133.4% in the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock valued at $20,024,000 after acquiring an additional 1,299,109 shares during the last quarter. Kopion Asset Management LLC lifted its position in Certara by 49.9% in the fourth quarter. Kopion Asset Management LLC now owns 982,710 shares of the company’s stock valued at $8,658,000 after acquiring an additional 327,064 shares during the last quarter. Topline Capital Management LLC purchased a new stake in Certara in the third quarter valued at $6,678,000. Finally, Brown Brothers Harriman & Co. lifted its position in Certara by 34.8% in the third quarter. Brown Brothers Harriman & Co. now owns 3,764,034 shares of the company’s stock valued at $45,996,000 after acquiring an additional 972,669 shares during the last quarter. Institutional investors and hedge funds own 73.96% of the company’s stock.

About Certara

(Get Free Report)

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.